Abstract
Characterized by their low prevalence, rare diseases are often chronically debilitating or life threatening. Despite their low prevalence, the aggregate number of individuals suffering from a rare disease is estimated to be nearly 400 million worldwide. Over the past decades, efforts from researchers, clinicians, and pharmaceutical industries have been focused on both the diagnosis and therapy of rare diseases. However, because of the lack of data and medical records for individual rare diseases and the high cost of orphan drug development, only limited progress has been achieved. In recent years, the rapid development of next-generation sequencing (NGS)-based technologies, as well as the popularity of precision medicine has facilitated a better understanding of rare diseases and their molecular etiology. As a result, molecular subclassification can be identified within each disease more clearly, significantly improving diagnostic accuracy. However, providing appropriate care for patients with rare diseases is still an enormous challenge. In this review, we provide a brief introduction to the challenges of rare disease research and make suggestions on where and how our efforts should be focused.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Arnedos, M., Vicier, C., Loi, S., Lefebvre, C., Michiels, S., Bonnefoi, H., and Andre, F. (2015). Precision medicine for metastatic breast cancer—limitations and solutions. Nat Rev Clin Oncol 12, 693–704.
Baldovino, S., Montserrat, A., Taruscio, D., Daina, E., and Roccatello, D. (2016). Rare diseases in Europe: from a wide to a local perspective. Isr Med Assoc J 18, 359–363..
Bavisetty, S., Grody, W.W., and Yazdani, S. (2013). Emergence of pediatric rare diseases. Rare Diss 1, e23579.
Bhattacharya, I., Manukyan, Z., Chan, P., Harnisch, L., and Heatherington, A. (2016). Making every subject count: a case study of drug development path for medication in a pediatric rare disease. Clin Pharmacol Ther 100, 330–332.
Bogdanova-Mihaylova, P., Alexander, M.D., Murphy, R.P., and Murphy, S.M. (2017). Waardenburg syndrome: a rare cause of inherited neuropathy due to SOX10 mutation. J Peripher Nerv Syst,.
Boycott, K.M., Vanstone, M.R., Bulman, D.E., and MacKenzie, A.E. (2013). Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet 14, 681–691.
Boycott, K.M., Vanstone, M.R., Bulman, D.E., and MacKenzie, A.E. (2013). Rare-disease genetics in the era of next-generation sequencing: Discovery to translation. Nat Rev Genet 14, 681–691..
Collins, F. (2011). An audience with...francis collins. Interviewed by Asher Mullard. Nat Rev Drug Discov 10, 14..
Collins, F.S., and Varmus, H. (2015). A new initiative on precision medicine. N Engl J Med 372, 793–795.
Ekins, S. (2017). Industrializing rare disease therapy discovery and development. Nat Biotechnol 35, 117–118.
Franco, P. (2013). Orphan drugs: the regulatory environment. Drug Discovery Today 18, 163–172.
Gong, S., Wang, Y., Pan, X., Zhang, L., Huang, R., Chen, X., Hu, J., Xu, Y., and Jin, S. (2016). The availability and affordability of orphan drugs for rare diseases in China. Orphanet J Rare Dis 11, 20.
Groza, T., Köhler, S., Moldenhauer, D., Vasilevsky, N., Baynam, G., Zemojtel, T., Schriml, L.M., Kibbe, W.A., Schofield, P.N., Beck, T., Vasant, D., Brookes, A.J., Zankl, A., Washington, N.L., Mungall, C.J., Lewis, S.E., Haendel, M.A., Parkinson, H., and Robinson, P.N. (2015). The human phenotype ontology: semantic unification of common and rare disease. Am J Human Genets 97, 111–124.
Hampton, T. (2006). Rare disease research gets boost. JAMA 295, 2836–2838..
Hilbert, J.E., Kissel, J.T., Luebbe, E.A., Martens, W.B., McDermott, M.P., Sanders, D.B., Tawil, R., Thornton, C.A., and Moxley Iii, R.T. (2012). If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemporary Clinical Trials 33, 302–311.
Howlader, N., Noone, A.M., Krapcho, M., Miller, D., Bishop, K., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., Chen, H.S., Feuer, E.J., and Cronin, K.A. (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.
Kraja, A.T., Czajkowski, J., Feitosa, M.F., Borecki, I.B., and Province, M.A. (2011). Detecting disease rare alleles using single SNPs in families and haplotyping in unrelated subjects from the Genetic Analysis Workshop 17 data. BMC Proc 5 Suppl 9: S96.
Lu, P., Chen, X., Feng, Y., Zeng, Q., Jiang, C., Zhu, X., Fan, G., and Xue, Z. (2016). Integrated transcriptome analysis of human iPS cells derived from a fragile X syndrome patient during neuronal differentiation. Sci China Life Sci 59, 1093–1105.
Manuti, B., Rizza, P., Bianco, A., Nobile, C.G., and Pavia, M. (2010). The quality of preventive health care delivered to adults: results from a crosssectional study in Southern Italy. BMC Public Health 10, 350.
Mascalzoni, D., Knoppers, B.M., Ayme, S., Macilotti, M., Dawkins, H., Woods, S., and Hansson, M.G. (2013). Rare diseases and now rare data? Nat Rev Genet 14, 372..
Migita, K., Izumi, Y., Jiuchi, Y., Iwanaga, N., Kawahara, C., Agematsu, K., Yachie, A., Masumoto, J., Fujikawa, K., Yamasaki, S., Nakamura, T., Ubara, Y., Koga, T., Nakashima, Y., Shimizu, T., Umeda, M., Nonaka, F., Yasunami, M., Eguchi, K., Yoshiura, K., and Kawakami, A. (2016). Familial Mediterranean fever is no longer a rare disease in Japan. Arthritis Res Ther 18, 175.
Mirnezami, R., Nicholson, J., and Darzi, A. (2012). Preparing for precision medicine. N Engl J Med 366, 489–491.
Nagel, G., Ünal, H., Rosenbohm, A., Ludolph, A.C., and Rothenbacher, D. (2013). Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) -registry Swabia. BMC Neurol 13, 22.
Nambot, S., Gavrilov, D., Thevenon, J., Bruel, A.L., Bainbridge, M., Rio, M., Goizet, C., Rotig, A., Jaeken, J., Niu, N., Xia, F., Vital, A., Houcinat, N., Mochel, F., Kuentz, P., Lehalle, D., Duffourd, Y., Riviere, J.B., Thauvin-Robinet, C., Beaudet, A.L., and Faivre, L. (2017). Further delineation of a rare recessive encephalomyopathy linked to mutations in GFER thanks to data sharing of whole exome sequencing data. Clin Genet.
Potter, B.K., Khangura, S.D., Tingley, K., Chakraborty, P., and Little, J. (2016). Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research? Genet Med 18, 117–123..
Ramoni, R.B., Mulvihill, J.J., Adams, D.R., Allard, P., Ashley, E.A., Bernstein, J.A., Gahl, W.A., Hamid, R., Loscalzo, J., McCray, A.T., Shashi, V., Tifft, C.J., and Wise, A.L. (2017). The undiagnosed diseases network: accelerating discovery about health and disease. Am J Human Genets 100, 185–192.
Reinecke, M., Rommel, K., and Schmidtke, J. (2011). Funding of rare disease research in Germany: a pilot study. J Community Genet 2, 101–105.
Rodwell, C. and Ayme, S. (2015). Rare disease policies to improve care for patients in Europe. Biochim Biophys Acta 1852(10 Pt B): 2329–2335..
Roy, A.J., van den Bergh, P., van Damme, P., Doggen, K., and van Casteren, V. (2015). Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR). Acta Neurol Belg 115, 97–104.
Rubinstein, Y.R., and McInnes, P. (2015). NIH/NCATS/GRDR® Common Data Elements: A leading force for standardized data collection. Contemporary Clinical Trials 42, 78–80.
Schriml, L.M., and Mitraka, E. (2015). The Disease Ontology: fostering interoperability between biological and clinical human disease-related data. Mamm Genome 26, 584–589.
Solomon, D.H., Shadick, N.A., Weinblatt, M.E., Frits, M., Iannaccone, C., Zak, A., and Korzenik, J.R. (2017). Clinical patient registry recruitment and retention: a survey of patients in two chronic disease registries. BMC Med Res Methodol 17, 59.
Steliarova-Foucher, E., Stiller, C., Lacour, B., and Kaatsch, P. (2005). International classification of childhood cancer, third edition. Cancer 103, 1457–1467.
Sykes, J., Cheng, L., Xu, W., Tsao, M.S., Liu, G., and Pintilie, M. (2011). Addition of multiple rare SNPs to known common variants improves the association between disease and gene in the Genetic Analysis Workshop 17 data. BMC Proc 5 Suppl 9: S97..
Trama, A., Marcos-Gragera, R., Sánchez Pérez, M.J., van der Zwan, J.M., Ardanaz, E., Bouchardy, C., Melchor, J.M., Martinez, C., Capocaccia, R., Vicentini, M., Siesling, S., and Gatta, G. (2017). Data quality in rare cancers registration: the report of the RARECARE data quality study. TJ 103, 22–32.
Veldhuijzen van Zanten, S.E.M., Baugh, J., Chaney, B., de Jongh, D., Sanchez Aliaga, E., Barkhof, F., Noltes, J., de Wolf, R., van Dijk, J., Cannarozzo, A., Damen-Korbijn, C.M., Lieverst, J.A., Colditz, N., Hoffmann, M., Warmuth-Metz, M., Bison, B., Jones, D.T.W., Sturm, D., Gielen, G.H., Jones, C., Hulleman, E., Calmon, R., Castel, D., Varlet, P., Giraud, G., Slavc, I., van Gool, S., Jacobs, S., Jadrijevic-Cvrlje, F., Sumerauer, D., Nysom, K., Pentikainen, V., Kivivuori, S.M., Leblond, P., Entz-Werle, N., von Bueren, A.O., Kattamis, A., Hargrave, D.R., Hauser, P., Garami, M., Thorarinsdottir, H.K., Pears, J., Gandola, L., Rutkauskiene, G., Janssens, G.O., Torsvik, I.K., Perek-Polnik, M., Gil-da-Costa, M.J., Zheludkova, O., Shats, L., Deak, L., Kitanovski, L., Cruz, O., Morales La Madrid, A., Holm, S., Gerber, N., Kebudi, R., Grundy, R., Lopez-Aguilar, E., Zapata-Tarres, M., Emmerik, J., Hayden, T., Bailey, S., Biassoni, V., Massimino, M., Grill, J., Vandertop, W.P., Kaspers, G.J.L., Fouladi, M., Kramm, C.M., and van Vuurden, D.G. (2017). Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. J Neurooncol 132, 255–266.
Waisbourd-Zinman, O., Surrey, L.F., Schwartz, A.E., Russo, P.A., and Wen, J. (2017). A rare BSEP mutation associated with a mild form of progressive familial intrahepatic cholestasis type 2. Ann Hepatol 16, 465–468..
Wellman-Labadie, O., and Zhou, Y. (2010). The USOrphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 95, 216–228..
Westfall, J.M., Mold, J., and Fagnan, L. (2007). Practice-based research—“Blue Highways” on the NIH roadmap. JAMA 297, 403–406.
Xu, R., Li, L., and Wang, Q. (2013). Towards building a disease-phenotype knowledge base: extracting disease-manifestation relationship from literature. Bioinformatics 29, 2186–2194.
Yang, L., Mei, T., Lin, X., Tang, H., Wu, Y., Wang, R., Liu, J., Shah, Z., and Liu, X. (2016). Current approaches to reduce or eliminate mitochondrial DNA mutations. Sci China Life Sci 59, 532–535.
Acknowledgements
This work was supported by the National High Technology Research and Development Program of China (2015AA020108, 2015AA020104), the National Science Foundation of China (31671377), and Shanghai 111 Project (B14019).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jia, J., Shi, T. Towards efficiency in rare disease research: what is distinctive and important?. Sci. China Life Sci. 60, 686–691 (2017). https://doi.org/10.1007/s11427-017-9099-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-017-9099-3